How are the ABVD and A+AVD regimens used in the treatment of Hodgkin lymphoma (Hodgkin disease)?

Updated: Sep 12, 2018
  • Author: Bradley W Lash, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

The ABVD regimen is the standard of care for the treatment of classical Hodgkin lymphoma, particularly in the United States. ABVD is superior to MOPP in terms of disease-free survival (DFS) and has a lower incidence of sterility and secondary leukemia. [53]

The A+AVD regimen is a modification of the ABVD regimen, with brentuximab vedotin added and bleomycin omitted. It is the newest FDA-approved regimen for patients with stage III or IV classic Hodgkin lymphoma. Approval was based on a phase III trial that showed improved modified progression-free survival (PFS) compared with ABVD. [54] However, this trial has received criticism over its use of modified PFS as opposed to standard PFS, and long-term outcomes are awaited.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!